Streetbeat News

Earnings

ALRM

Alarm.com Holdings (NASDAQ:ALRM) is scheduled to release its quarterly earnings report on February 22, 2024. Analysts predict an EPS of $0.47. The company's past earnings performance shows a history of beating EPS estimates, leading to significant stock price movements. Shares are currently trading at $69.02, with a 52-week increase of 31.13%. Investors are advised to watch for the company's guidance for future growth, as it can significantly impact stock prices.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

NOG

Northern Oil & Gas (NYSE:NOG) is scheduled to release its quarterly earnings report on February 22, 2024. Analysts predict an EPS of $1.69. The company's past earnings performance shows a mix of hits and misses against estimates, with share price reactions varying accordingly. Shares are currently trading at $33.57, reflecting a 9.04% increase over the last 52 weeks. Investors are keenly awaiting the report and guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

NTLA

Intellia Therapeutics (NASDAQ:NTLA) is scheduled to release its quarterly earnings report on February 22, 2024, with an expected EPS of $-1.45. Historical data shows mixed reactions to past earnings, with the last quarter beating estimates but resulting in a 3.33% share price drop. Over the last year, NTLA shares have declined by 32.31%, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

NEO

NeoGenomics Inc (NASDAQ:NEO) reported a Q4 2023 adjusted EPS of $0.03, surpassing consensus estimates and marking a turnaround from a previous loss. Sales rose 12.1% Y/Y to $155.55 million, also beating estimates. The company saw a 20% increase in Clinical Services revenue and a 17% decrease in Advanced Diagnostics revenue. Adjusted gross profit margin improved to 46.7%. Despite a net loss decrease to $14 million, adjusted EBITDA was positive at $9 million. For FY 2024, NeoGenomics forecasts an adjusted EPS of $0.04, against a consensus loss of $(0.08). William Blair maintains an Outperform rating, viewing legal issues as a temporary concern.

Portfolio Pulse from Vandana Singh

February 21, 2024 | 4:01 pm

PCG

PG&E (NYSE:PCG) is scheduled to release its quarterly earnings report on February 22, 2024, with analysts estimating an EPS of $0.45. The company's past earnings performance shows a mix of hits and misses against estimates, affecting stock prices variably. Shares are currently trading at $16.63, reflecting a 9.2% increase over the last 52 weeks. Investors are looking for positive guidance for the next quarter beyond the EPS figures.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

RKT

Rocket Companies (NYSE:RKT) is anticipated to report a quarterly EPS of $-0.04 on February 22, 2024. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, Rocket Companies has had a mixed record of beating EPS estimates, with share price reactions varying accordingly. The stock has seen a 36.85% increase over the last 52 weeks, trading at $11.15 as of February 20.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

SQ

Block (NYSE:SQ) is scheduled to release its quarterly earnings report on February 22, 2024, with analysts estimating an EPS of $0.59. Historical data shows Block has had mixed earnings performance, with a notable 10.69% share price increase following last quarter's earnings beat. Shares are currently trading at $65.73, down 13.14% over the last year. Investors are keenly awaiting the report and guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

IDYA

IDEAYA Biosciences (NASDAQ:IDYA) has seen varied analyst opinions over the past quarter, with recent updates showing a shift towards more bullish stances. The average 12-month price target has increased to $46.5, up from $37.20, indicating a positive outlook on the company's future. Analysts from firms like RBC Capital and Goldman Sachs have raised their price targets, reflecting optimism about IDEAYA's market position and its oncology-focused precision medicine developments. Despite a significant revenue decline of -72.94% as of September 30, 2023, the company's strong net margin and ROE suggest effective cost control and equity capital utilization.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

SPXC

SPX Techs (NYSE:SPXC) is scheduled to release its quarterly earnings report on February 22, 2024. Analysts predict an EPS of $1.26. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting variably. Shares are currently trading at $108.51, up 48.14% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

PLTR

The article provides a detailed comparison of Palantir Technologies (PLTR) against its competitors in the Software industry, focusing on key financial metrics such as P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Palantir's P/E ratio is significantly higher than the industry average, suggesting overvaluation, while its P/B ratio indicates potential undervaluation. The company's P/S ratio is also high, implying overvaluation in terms of sales performance. Palantir shows lower profitability and growth potential compared to its peers, with a lower ROE, EBITDA, gross profit, and revenue growth rate. Additionally, Palantir has a lower debt-to-equity ratio compared to its top 4 peers, indicating a stronger financial position.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:00 pm